Results 121 to 130 of about 38,942 (318)
ABSTRACT Background To evaluate the 10‐year cumulative incidence, progression rates, and risk factors for macular atrophy (MA) in neovascular age‐related macular degeneration (nAMD) patients receiving long‐term anti‐vascular endothelial growth factor (VEGF) therapy.
Francesco Romano+13 more
wiley +1 more source
Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up [PDF]
PURPOSE: To evaluate the 36-month efficacy of intravitreal ranibizumab injections for choroidal neovascularization secondary to age-related macular degeneration (AMD) in real world clinical practice.
Faria de Abreu, JR+6 more
core +1 more source
Transplantation of stem cell‐derived photoreceptors in retinal repair. We summarize methods for differentiating stem cells and describe surgical techniques for transplanting photoreceptor precursors to restore visual function (A). The effectiveness of these techniques is assessed with behavioral (B) and in vitro assays (C) using mouse models that mimic
Darin Zerti+5 more
wiley +1 more source
Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular ...
Fong AH, Lai TY
doaj
AIM:To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) vs ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).METHODS:The Cochrane Central Register of Controlled Trials (CENTRAL)
Jun-Kang Si+9 more
doaj +1 more source
Health State Utility Values for Age-Related Macular Degeneration: Review and Advice [PDF]
Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de novo utility ...
Butt, T, Rubin, G, Tufail, A
core +1 more source
Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review
ABSTRACT Host cell proteins (HCP) are process‐related impurities that can co‐purify with therapeutic proteins. Some HCP impurities potentially can have an impact on patient safety (immunogenicity or toxicity), efficacy, and/or product quality. It is important to reduce the levels of HCP impurities with a well‐controlled manufacturing process and to ...
Lisette Coye+19 more
wiley +1 more source
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Régnier SA+3 more
doaj
Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases [PDF]
published_or_final_versio
Behar-Cohen, F+8 more
core +1 more source
Stabilizing choroidal neovessels offers a novel treatment‐option for pathological CNV. Pigment epithelium‐derived factor (PEDF), a multifunctional protein with vessel‐stabilizing properties, is a promising candidate for this approach. Its efficacy with and without bevacizumab was tested in a VEGF overexpression CNV rat model.
Alexander V. Tschulakow+3 more
wiley +1 more source